Granules India Performance
- Today's Low
- ₹782
- Today's High
- ₹797
- 52 Week Low
- ₹433
- 52 Week High
- ₹804
- Open Price₹795
- Previous Close₹794
- Volume504,165
- 50 DMA₹707.03
- 100 DMA₹659.41
- 200 DMA₹612.18
Granules India Chart
Investment Returns
- Over 1 Month + 13.1%
- Over 3 Month + 37.77%
- Over 6 Month + 39.25%
- Over 1 Year + 51.74%
Smart Investing Starts Here Start SIP with Granules India for Steady Growth!
Granules India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 33
- PEG Ratio
- 1.8
- Market Cap Cr
- 19,609
- P/B Ratio
- 4.7
- Average True Range
- 23.01
- EPS
- 24.32
- Dividend Yield
- 0.2
- MACD Signal
- 25.99
- RSI
- 70.51
- MFI
- 87.11
Latest Stock News Updates
Conference Call with Granules India Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.
- Trendlyne
- 1 month ago
Pharmaceuticals company Granules India announced Q4FY26 & FY26 results Q4FY26 Standalone Financial Highlights: Total Revenue from operations: Rs 8,768.21 million in Q4FY26, compared to Rs 8,953.18 million in Q3FY26 (down 2.07% QoQ) and Rs 7,680.26 million in Q4FY25 (up 14.17% YoY). Total Income: Rs 8,935.08 million in Q4FY26, compared to Rs 9,073.97 million in Q3FY26 (down 1.53% QoQ) and Rs 7,985.11 million in Q4FY25 (up 11.90% YoY). Net Profit for the period: Rs 989.87 million in Q4FY26, compared to Rs 1,115.82 million in Q3FY26 (down 11.29% QoQ) and Rs 940.54 million in Q4FY25 (up 5.24% YoY). Basic EPS: Rs 4.04 in Q4FY26, compared to Rs 4.60 in Q3FY26 and Rs 3.88 in Q4FY25. Q4FY26 Consolidated Financial Highlights: Total Revenue from operations: Rs 14,706.08 million in Q4FY26, compared to Rs 13,879.40 million in Q3FY26 (up 5.96% QoQ) and Rs 11,974.29 million in Q4FY25 (up 22.81% YoY). Total Income: Rs 14,793.82 million in Q4FY26, compared to Rs 13,842.99 million in Q3FY26 (up 6.87% QoQ) and Rs 11,993.53 million in Q4FY25 (up 23.35% YoY). Net Profit for the period: Rs 2,015.68 million in Q4FY26, compared to Rs 1,502.11 million in Q3FY26 (up 34.19% QoQ) and Rs 1,520.31 million in Q4FY25 (up 32.58% YoY). Basic EPS: Rs 8.23 in Q4FY26, compared to Rs 6.19 in Q3FY26 and Rs 6.27 in Q4FY25. FY26 Standalone Financial Highlights: Total Revenue from operations: Rs 34,739.60 million in FY26, compared to Rs 30,301.63 million in FY25 (up 14.65% YoY). Total Income: Rs 35,237.63 million in FY26, compared to Rs 30,708.43 million in FY25 (up 14.75% YoY). Net Profit for the year: Rs 4,006.67 million in FY26, compared to Rs 3,193.36 million in FY25 (up 25.47% YoY). Net cash generated from operating activities: Rs 6,433.19 million in FY26, compared to Rs 8,227.06 million in FY25 (down 21.80% YoY). Basic EPS: Rs 16.48 in FY26, compared to Rs 13.17 in FY25 (up 25.13% YoY). Dividend: The Board of Directors recommended a final dividend of Rs 1.75 per equity share of face value Rs 1 each. FY26 Consolidated Financial Highlights: Total Revenue from operations: Rs 53,656.42 million in FY26, compared to Rs 44,816.08 million in FY25 (up 19.73% YoY). Total Income: Rs 53,859.71 million in FY26, compared to Rs 44,945.27 million in FY25 (up 19.83% YoY). Net Profit for the year: Rs 5,950.21 million in FY26, compared to Rs 5,015.16 million in FY25 (up 18.64% YoY). Net cash generated from operating activities: Rs 8,802.38 million in FY26, compared to Rs 4,661.14 million in FY25 (up 88.85% YoY). Basic EPS: Rs 24.47 in FY26, compared to Rs 20.69 in FY25 (up 18.27% YoY). Business Highlights: Acquisitions & Expansion: Completed the acquisition of Senn Chemicals AG, Switzerland, which became a wholly owned step-down subsidiary effective April 10, 2025. Acquired a 100% stake in Granules Pharmaceuticals GmbH (formerly Optus 1039 GmbH), Germany, on November 20, 2025, for a consideration of EUR 28,400. Incorporated a new subsidiary, Granules Pharmaceuticals Canada, Inc., on November 26, 2025. Fund Raising: Approved the issuance of 25,000,000 convertible warrants on a preferential basis, totaling Rs 14,625 million at Rs 585 per warrant. The company received Rs 3,656.25 million (25% consideration) on February 23, 2026. Allotted 5,128,205 equity shares to non-promoter members on a preferential basis during FY26. Regulatory Status: The Gagillapur facility received a USFDA warning letter in February 2025. The company has implemented remedial measures, including engaging three independent consultants for corrective and preventive actions. Slowdown in production at this facility impacted revenue and increased air freight and consultancy costs. Investments: Disposed of an investment in US Pharma Ltd., recording a gain of USD 2.96 million (Rs 263.39 million) during the year. Result PDF
- Trendlyne
- 1 month ago
Granules India, which is globally one of the largest paracetamol makers and a major player in the active pharmaceutical ingredients market, derives a bulk of its revenue from the US
- Business Line
- 1 month 3 weeks ago
Granules India Financials
Granules India Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹755.75
- 50 Day
- ₹707.03
- 100 Day
- ₹659.41
- 200 Day
- ₹612.18
Resistance and Support
- R3 814.43
- R2 805.92
- R1 798.63
- S1 782.83
- S2 774.32
- S3 767.03
Granules India Corporate Actions - Bonus, Splits, Dividends
About Granules India
Granules India Ltd. is vertically integrated pharmaceutical company based in India, specializing in manufacturing of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), & finished dosages. Established in 1984, company has strong presence in global pharmaceutical market, supplying its products to over 300 customers in more than 60 countries. Granules India's focus on cost-efficient manufacturing, quality assurance, & regulatory compliance has enabled it to become trusted partner for leading pharmaceutical companies worldwide. company's commitment to innovation & expansion has driven its growth in highly competitive pharmaceutical industry.
With six tons of batch processing capacity, it is one of biggest PFI makers in India. Since its PFIs are made to transfer straight from drums to hoppers, it has established itself as top supplier to major international pharmaceutical corporations.
The strategy focus on high-value formulations & drop in API sales are to blame for change in revenue contribution.
Beyond top five heritage items, company is expanding its product line; as of FY24, new products account for 25% of total sales, up from 19% in FY22.
- NSE Symbol
- GRANULES
- BSE Symbol
- 532482
- Chairman & Managing Director
- Dr. Krishna Prasad Chigurupati
- ISIN
- INE101D01020
Similar Stocks to Granules India
Popular Stocks
Granules India FAQs
Granules India share price is ₹791 As on 05 June, 2026 | 06:10
The Market Cap of Granules India is ₹19609.4 Cr As on 05 June, 2026 | 06:10
The P/E ratio of Granules India is 33 As on 05 June, 2026 | 06:10
The PB ratio of Granules India is 4.7 As on 05 June, 2026 | 06:10
Consider company's market position in pharmaceutical industry & its growth prospects before investing.
Key metrics include revenue from key products, profit margins, & regulatory approvals.
Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Granules India share, you can then put order as you prefer.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.